MISGAV, Israel & LONDON--(BUSINESS WIRE)--Medgenics (AIM:MEDG), the US-incorporated biopharmaceutical company, is pleased to provide an update on progress towards the start of its Phase I/II clinical trials with EPODURE, its lead sustained-action protein therapy for producing and delivering erythropoietin (EPO) to treat anaemia.
